SpeedWeed

MARCH 11, 2021

“The case is about seeking to ensure that patients with serious, life-threatening illness are able to realize the promise of state and federal Right to Try laws and access psilocybin for therapeutic purposes.”. At that point, the team decided to sue the DEA to change its decision. “I We don’t have much of an explanation at all.”

DEA 52

DEA Patients Access Advocacy 52

Cannabis Law Report

NOVEMBER 2, 2022

Drug Enforcement Administration and the legal team representing terminally ill patients petitioning for access to psilocybin-assisted therapy. In late September, the DEA denied an official petition requesting that the agency look into rescheduling psilocybin from Schedule I to Schedule II.

Microdosing 52

Microdosing DEA Therapy Access 52

Cannabis Law Report

MAY 10, 2022

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Marijuana Moment reports. DeaOutoftheway @RTTpsilocybin pic.twitter.com/1NJWt2cJWn. aeidinger) May 9, 2022.

DEA 52

DEA Therapy Access Patients 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ? .

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. Drug Enforcement Agency (DEA). This means that U.S. Is the future exciting? .”

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

APRIL 21, 2022

Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . Promising clinical trial results have generated much interest in studying MDMA as a catalyst to therapy for PTSD and related conditions — and an increased demand for pharmaceutical-grade MDMA.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Veriheal

AUGUST 24, 2022

Any sales of psychedelic compounds would still be strictly prohibited; however, the initiative would allow for people to offer psychedelic services such as guidance and therapy or for harm reduction or spiritual purposes with or without payment. Not all alternative medicine advocates are in support of the Natural Medicine Health Act, however.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Cannabis Law Report

JULY 9, 2021

The use of psychedelic substances to treat mental illness and physical disorders is known as “psychedelic therapy.” In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

NewsMunchies

NOVEMBER 12, 2021

State-level ballot measures may further broaden the legal circumstances and settings in which psychedelics can be used for mental health therapy. The problem is, under federal law, psilocybin remains a prohibited Schedule 1 Drug, defined by the DEA as having “no currently accepted medical use and a high potential for abuse.”

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

SpeedWeed

MAY 15, 2021

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects were randomly divided into two groups, each of which received three individual sessions of talk therapy. Image via. View original article.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

FEBRUARY 28, 2022

Moreover, because Indigenous communities pioneered many aspects of modern psychedelic therapies, their patenting by Western corporations may promote biopiracy, the exploitation of Indigenous knowledge without compensation. MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” 5520), and the Veterans Equal Access Act (H.R. However, it is clear that there is momentum to give veterans access to cannabis.

Law 62

Law Chronic Pain Conditions Legislation 62

Veriheal

DECEMBER 27, 2022

Scientists Hope New Findings Will Help Expand Research on Psychedelic Therapy. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .

Research and Development 95

Research and Development Therapy Consumption DEA 95

Cannabis Law Report

MAY 31, 2022

Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. Breakthrough Therapy status obtained by COMPASS Pathways and Usona Institute. Breakthrough Therapy.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

MedicalJane

JUNE 29, 2018

. “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.” The Next Move Is On The DEA. Epidiolex’s launch is in the hands of the DEA. ” –FDA Commissioner Scott Gottlieb.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Canna Care Docs

SEPTEMBER 26, 2019

Powered by Sail, we are on a mission to solve the issue of cannabis access for patients. An open-minded approach toward alternative therapies Possess an active Connecticut medical license issued by the Connecticut Department of Public Health. WE ARE SEEKING LICENSED MD OR ARPNs for our Hartford, CT clinic. About Canna Care Docs….

History 40

History DEA Therapy Patients 40

SpeedWeed

AUGUST 16, 2021

And we’re gonna have to change therapies to try to win this battle. Lepp was one of the industry’s greatest advocates, leaving his mark as one of many who suffered in prison as a result of trying to cultivate medical cannabis and help patients get access. I have cancer of the bone now. And it’s pretty rampant from my chest to my toes.

DEA 52

DEA Patients Therapy Cannabis 52

Veriheal

JUNE 29, 2021

In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. The FDA refers to this program as the expanded access program on their website. Cannabinoid Therapies for Cancer Patients. A Push by Patients.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. For this event , panelists such as MAPS researcher Dorna Pourang and attorney Matt Zorn would talk about “the state of psychedelic therapy, the challenges and opportunities ahead, and how the medical system will make room for psychedelics.”. Psychedelics in the Healthcare System.

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Canna Law Blog

NOVEMBER 6, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. For two decades, U.S.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105

Law Research and Development Therapy DEA 105

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Therapy 90

Therapy Legalization Chronic Pain DEA 90

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY. ” Mr. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Canna Law Blog

MARCH 4, 2020

In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

The Cannigma

MAY 15, 2023

While costs to access ketamine therapy can be high in some locations, and like any drug ketamine is not a cure-all, some patients and their doctors have been reporting life-changing results when no other treatment provided relief. 1 Related Stories What’s the deal with ketamine? 1 Related Stories What’s the deal with ketamine?

Therapy 78

Therapy Access Blood Pressure Treatment 78

Sensi Seeds

NOVEMBER 28, 2018

Food and Drug Administration (FDA) earlier this year, and convince the DEA to reclassify CBD from a Schedule I (most restrictive category) to a Schedule V drug (least restrictive category.) As a result, GW’s latest CBD product, EPIDIOLEX ® was entered into the Spanish pharmacopeia over the summer.

CBD 71

CBD Seed-To-Sale Food Research and Development 71

Veriheal

FEBRUARY 23, 2024

As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. Countless veterans suffer from these ailments, and, as such, are pushing for access to as many treatments and therapies as possible.

DEA 99

DEA Chronic Pain Treatment Therapy 99

The Cannigma

FEBRUARY 16, 2022

So, with that, we should get into it, but don’t forget to check out our segment with Americans for Safe Access. We always have a nice little tidbit when we’re all about advocacy and access to cannabis for all. It’s Dr. Codi Peterson here with our regularly scheduled segment with Americans for Safe Access.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

Cannabis Law Report

APRIL 4, 2022

Congress, signed into law by President Trump, with 41 state enactments, give terminally ill patients access to experimental medicines still in development? But the Drug Enforcement Agency is barring access to one such experimental medicine: psilocybin, also known in its fungal form as “magic mushrooms.”. Read more at.

Access 52

Access Patients DEA Research and Development 52

SpeedWeed

JULY 22, 2021

The attorney general can also choose to waive that right and let the DEA review the petition instead. . Each day cannabis remains overly scheduled, patients and researchers across the United States continue to lose access to life-saving therapies and data.”. And Joyce and Young’s cannabis activism doesn’t end there.

DEA 52

DEA Therapy Cannabis Patients 52

Cannabis Law Report

JULY 30, 2019

Like others, Dr. Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Cannabis is not a “gateway” drug, according to the ASA and the DEA’s own statements cited in the August 2016 U.S.

Marijuana 45

Marijuana Patients Research and Development Programs 45